Wedbush Lowers Earnings Estimates for Artiva Biotherapeutics

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush decreased their FY2024 earnings estimates for shares of Artiva Biotherapeutics in a report issued on Wednesday, November 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of ($5.08) for the year, down from their previous estimate of ($4.55). Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.60) per share. Wedbush also issued estimates for Artiva Biotherapeutics' FY2025 earnings at ($2.61) EPS, FY2026 earnings at ($2.76) EPS and FY2027 earnings at ($2.91) EPS.

Several other analysts also recently issued reports on the company. Cantor Fitzgerald began coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an "overweight" rating and a $23.00 price objective on the stock. Jefferies Financial Group initiated coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a "buy" rating and a $21.00 price target for the company. Needham & Company LLC reiterated a "buy" rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Wednesday. Finally, TD Cowen started coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a "buy" rating for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Artiva Biotherapeutics currently has an average rating of "Buy" and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Down 4.3 %

Shares of Artiva Biotherapeutics stock traded down $0.45 on Friday, reaching $10.06. 97,366 shares of the company were exchanged, compared to its average volume of 138,613. Artiva Biotherapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $17.31. The business has a fifty day simple moving average of $12.57.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24).

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. purchased a new position in Artiva Biotherapeutics in the third quarter valued at about $623,000. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $42,000. MetLife Investment Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $135,000. Acuta Capital Partners LLC acquired a new position in Artiva Biotherapeutics in the third quarter worth approximately $680,000. Finally, RTW Investments LP bought a new position in Artiva Biotherapeutics during the third quarter valued at approximately $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.